About Novus Capital

  • Novus Capital specializes in M&A advisory for mid market transactions in Russia, the CIS countries and the Baltic States
  • Members of our team are professional investment bankers with more than 10 years of experience, who organized and closed a number of prominent transactions on the Russian pharmaceutical market. Our team has successfully advised transactions with the total value of more than USD 2bn, including 450m in pharmaceutical industry
  • We specialize in pharmaceutical market as well as work in TMT, logistics and FMCG sectors
  • Our services include:
    • advisory in M&A transactions
    • advisory in capital raising transactions
    • advisory in in/out-licensing projects
  • As of today Novus Capital is engaged in a number of projects where it advises on the acquisition and sale of assets on the pharmaceutical and other markets, including deals for sale/acquisition of manufacturing facilities, sale/acquisition of product portfolios and individual brands
  • Novus Capital team has a wide network in Russia and the CIS countries in pharmaceutical sector with direct access to owners / top management of local companies and top management of multinational companies
  • Since 2016 Novus Capital has entered into strategic partnership with Torreya Partners, a leading independent investment banking and advisory firm in the USA providing services to life sciences companies globally with offices in New York, London and Mumbai. Since its inception in 2007 Torreya Partners has completed close to 200 transactions with a total value of over USD 100bn

Our positions

Transactions

Rank House
Value (USD m)
Number of Deals
1 Novus Capital
557
8
2 BIC Securities
301
5
3 Rothschild
829
3
4 Citigroup
743
3
5 Renaissance Capital
100
1

Source: Mergermarket, Novus Capital analysis

Note: Announced deals in the pharmaceutical industry in Russia in 2012-2017

Our services

Advisory in M&A transactions

Novus Capital provides a full range of advisory services in M&A transactions: sale and acquisitions of companies/assets, devision of the companies and mergers. Our team engages industry experts and market specialists that helps us evaluating the rationale and deal probability.

Due to our deep industry knowledge and understanding the specifics of the regulatory environment on the Russian pharmaceutical market our team has built long terms relationship with the top management and owners of Russian and multinational companies as well as with other market stakeholders (media, regulatory and public bodies). The combination of all of the above factors help us to be engaged in key M&A transactions on the Russian market.

In M&A transactions we:

  • advise our clients on the strategic issues
  • prepare pre-deal evaluation of the company/assets
  • prepare marketing materials (investment teaser, information memorandum and other presentation materials)
  • identify potential investors that are interested to acquire (in case of sell-side engagements) or acquisition targets that are interested to be acquired (in case of buy-side engagements)
  • organise the negotiations process
  • help agreeing deal structure and key deal parameters
  • coordinate the due diligence process of the target companies
  • help in selection of legal advisers and support in the preparation of transaction documentation, signing and closing of the deal

Our services

Advisory in capital raising transactions

Novus Capital advises in capital raising transactions for companies willing to finance its development. We help determining the necessary size of the investment capital, optimal split between equity and debt financing, deal structure as well as the list of the most probable investors/lenders.

In capital raising transaction we:

  • evaluate the company’s business plan and/or prepare the business plan
  • prepare the documents for the tender process among the potential investors (investment teaser, information memorandum and other presentation materials)
  • contact potential investors and present the business plan of the company
  • solicit the offers from the potential investors and analyse them
  • coordinate the due diligence process
  • in cooperation with legal and tax experts help in developing the most optimal deal structure
  • assist in negotiating and agreeing the deal structure and key deal terms with a selected investor
  • help in selection of legal advisers and support in the preparation of transaction documentation, signing and closing of the deal

Our services

Advisory in in/out-licensing projects

Novus Capital advises Russian and international pharmaceutical companies in projects for product in-licensing and product out-licensing

In licensing projects we:

  • prepare marketing materials (product profile, product memorandum and other presentation materials)
  • identify potential licensing partners
  • organise the negotiations process
  • assist in development, negotiations of deal structure and key deal terms with a selected partner
  • coordinate the due diligence process
  • help in selection of legal advisers and support in the preparation and signing of project documentation
2017
alsi-xantis
Sale of ALSI Pharma

Novus Capital acted as the financial adviser for the owners of Russian company ALSI Pharma in the sale to the strategic investor Xantis Pharma. ALSI Pharma is a leading company in Russia manufacturing generics. The company specilizes in production of cardiovascular products and drugs for cenral nervous system.

 

2016
dolfin
Divesture of Dolphin brand portfolio

Novus Capital acted as financial advisers for the owners of Dolphin product line, a leading over-the-counter product (medical device) for the treatment of sinusitis (infections of the paranasal sinus) in Russia, in business sale to American company Alvogen

2015
orvirem
SALE OF ORVIREM BRAND
Novus Capital team advised the owners of Russian pharmaceutical company Diod on sale of rights for Orvirem, ARVI and flu cure drug, to american company Alvogen
2015
sanitas2
ACQUISITION OF MANUFACTURING FACILITY IN LITHUANIA
Novus Capital team advised the owners of Russian pharmaceutical company Materia Medica on the acquisition of a pharmaceutical manufacturing company in Lithuania from Valeant Pharmaceuticals International
2014/2015
client4
JV IN PHARMACEUTICAL COMMUNICATIONS BETWEEN AARON LLOYD AND DENTSU AEGIS NETWORK

Novus Capital acted as the financial advisor to a leading Russian pharmaceutical communication agency Aaron Lloyd in the creation of the joint venture in Russia with the leading global communications agency Dentsu Aegis Network

2014
client1

TOTAL USD 180 M

DIVESTURE OF AQUALOR BRAND PORTFOLIO TO STADA ARZNEIMITTEL AG

Novus Capital partners acted as the financial advisors to the owners of Aqualor brand, the leading over-the-counter product for rinsing the nasal cavity on the Russian market, in selling the product to the strategic investor

2012
client3

TOTAL USD 100 M

DIVESTURE OF FIVE BRANDS’ PORTFOLIO

Novus Capital partners acted as the financial advisors to Akvion, one of the leading manufacturers of food supplements and pharmaceutical products on the Russian market, in selling the portfolio of five products to the strategic investor

2012
client2
SALE OF PHARMEXPERT GROUP’S INTELLECTUAL PROPERTY

Novus Capital partners acted as the financial advisors to Pharmexpert Group, the leading analytical company for the pharmaceutical industry in Russia, in negotiations, structuring and closing the sale of its business to IMS Health - a leading provider of information, services and technology for the healthcare industry globally

Current project
Ampoule

The sale of a neurological product at the clinical testing stage
Current project
Gamma project

Sale of the innovative product for ARVI and influenza virus infection in Russia
Current project
Project Jupiter

Advising on the sale of pharmacy chain
Current project
Project Lion

Advising the international company on acquisition of the portfolio of pharmaceutical products in Russia
Current project
Project Live

Advising on the sale of the Russian pharmaceutical company
Current project
Project Sky

Advising on acquisition of pharmaceutical products in Russia and CIS
Current project
Project Saturn

Advising on the sale of API manufacturer in Russia
Current project
Project Leader

Advising on the sale of portfolio of leading immunomodulating drugs in Russia
Current project
Project Amfita

Advising on the sale of food supplements company in Russia
Current project
Project Ocean

Advising on the sale of one the largest portfolios of food supplements in Russia
Sergey Orekhov

Partner

SOrekhov@novuscapital.ru
Sergey focuses on mergers and acquisitions and capital raising advisory in Russia. Sergey has been managing numerous M&A engagements in various industries, including pharmaceuticals, FMCG, banking, packaging, metals and mining, oil & gas and others.

Before BIC Securities Sergey worked at KMPG Corporate Finance (Moscow office) for more than 3 years, where he was involved in M&A and fund raising projects.

Sergey graduated from Finance University under the Government of the Russian Federation.

Aleksandr Lobakov

Managing Partner

Aleksandr.Lobakov@novuscapital.ru
Aleksandr focuses on mergers and acquisitions and capital raising advisory. Aleksandr has been advising and managing M&A transactions in pharmaceuticals, media, industrial packaging, food and beverages.

Before establishing Novus Capital, Aleksandr worked at BIC Securities as a Managing Director and Head of Pharmaceutical and Healthcare practice for more than 5 years. Before BIC Securities, in 2004-2009 Aleksandr was working at Partner position in Prudentia, one of the leading Baltic investment banking firms. During his work in Prudentia Aleksandr specialized in origination and execution of numerous corporate finance advisory engagements and M&A projects. Prior to Prudentia Aleksandr worked in the Corporate Advisory Services Department in Ernst & Young Baltic, as an Economist in the Analytical Department of the Central Bank of Latvia, and also as an Analyst at the Riga Stock Exchange.

Aleksandr holds a B.Sc. degree in Economics from the Stockholm School of Economics in Riga. He has also taken courses in Economics and Business from the Harvard Business School and completed the first level of CFA examination.

Valeriy Rusakov

Vice President

Valeriy.Rusakov@novuscapital.ru
Valeriy focuses on mergers and acquisitions (M&A) in healthcare, pharmaceutical and biotechnology industries in Russia



Prior to joining Novus Capital, Valeriy 2.5 years worked in BIC Securities as Senior Associate, where he was responsible for M&A transactions in pharmaceutical industry. Prior to joining BIC Securities, in 2008-2013 Valeriy worked as a Chief Investment Analyst in a healthcare group in Rusnano, Russian state PE/VC Company, where he was responsible for deal structuring, financial modeling, investment documentation preparation and due diligence processes. Valeriy participated in 8 closed deals and made numerous analysis of project applications.

Prior to joining Rusnano, Valeriy worked as an Analyst in Ernst & Young, valuation group, where he was engaged in projects in construction & development, media, energy and business engineering and was responsible for financial modeling, company and industry analysis, and performed business, assets and securities valuation. Before joining Ernst & Young, he worked for two years as an Auditor Assistant in audit department of Deloitte & Touche CIS in telecommunication, media and technology industry, where he performed audit of financial statement under RAS, IFRS & GAAP standards.

Valeriy holds a master degree in Economics, Corporate Finance from National Research University – Higher School of Economics. In addition, he successfully passed levels 1 and 2 of CFA examination.

Nikita Shinkarev

Senior Analyst

Nikita focuses on mergers and acquisitions and capital raising advisory in Russia. He has experience in pharmaceuticals, telecommunications, retail, oil and gas and financial sectors

Prior to joining to Novus Capital, Nikita for 2 years worked in international consulting company Deloitte as Consultant in Financial Advisory Services department where he was involved in several M&A, capital raising and due diligence projects in different sectors. Added to that, Nikita also worked in international company KPMG in audit department

Nikita graduated from Finance University under the Government of the Russian Federation and passed F1-F3 and F7 exams of ACCA qualification

Since 2016 Novus Capital has entered into strategic partnership with Torreya Partners.

Torreya Partners is a leading corporate finance advisory boutique serving companies in the life sciences industry. Torreya has grown to have more than 35 professionals and a global presence in life sciences advisory and it has successfully completed close to 200 assignments with a total value of over USD 100bn since they started in August 2007. Torreya has its primary offices in London, Mumbai, and New York. Torreya's work has taken place in pharmaceuticals, biotechnology, medical technology, diagnostics, nutritionals, pharma services and closely related sectors. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks.
Since 2016 Novus Capital has been cooperating with Baltic Partners on the Ukrainian market.

Baltic Partners provides independent financial advisory services to its clients in the Baltic countries, Ukraine, Russia and CEE.
Since 2015 Novus Capital has been cooperating with Mane Capital on the Bulgarian market.

Mane Capital is an independent investment banking boutique and the direct successor of the successful investment banking practice of KBC Securities in Bulgaria. Mane Capital specialises in strategic and financial advice, together with capital raising solutions for both private and public companies. By forming partnerships, and working with these companies at all stages of their development, Mane Capital is able to help structure and execute the widest range of corporate finance solutions.
Since 2017 Novus Capital has entered into strategic partnership with The Harel Group in the area of in/out-licensing transactions

The Harel Group main business is in facilitation of licensing and distribution arrangements between leading local and regional companies and US/Europe/Japan-innovative based pharmaceutical/biotech/medical device companies.

Careers

We believe that one of Novus Capital's success factors is our result orient team
We would be happy to invite to our team goal oriented people with good education and relevant experience, that are willing to reach new professional heights
If you are interested to join Novus Capital please send your CV to admin@novuscapital.ru

News

The Cabinet of Ministers rejected the idea to allow the sale of pharmaceuticals in grocery stores

The Cabinet of Ministers rejected the idea to allow the sale of pharmaceuticals in grocery stores

In Russia nonprescription drugs will not be sold in trade networks, Kommersant reports. The bill draft, ratifying cease of the monopoly of pharmacies for these drugs, was criticized by representatives of the pharmaceutical industry and the Ministry of Health.

Contacts

Office in Russia

Email: admin@novuscapital.ru
Federation Tower || Tower West, 41st floor
12 Presnenskaya nab.
Moscow, 123100, Russia